Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia), complicated intra-abdominal and urinary tract infections.

Doripenem is a carbapenem with a broad spectrum of activity. It inhibits bacterial cell wall biosynthesis and is indicated for the treatment of serious infections in secondary care.

Doripenem is given by infusion over one to four hours every eight hours. The longer infusion period should be considered when the infection is caused by less susceptible pathogens; extending the infusion time maximises the period when the plasma concentration exceeds the minimum inhibitory concentration.

Species resistant to other carbapenems do generally express co-resistance to doripenem.

View Doribax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases